Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CIMA guidance

This article was originally published in The Tan Sheet

Executive Summary

Expected investment banking, legal and administrative expenses in the $3.5 mil. to $4 mil. range connected with firm's proposed merger with aaiPharma cause CIMA Labs to lower third quarter earnings per share guidance to between 3¢ and 6¢, the company announced Oct. 9. The firm, which licenses orally-disintegrating drug technologies, previously expected EPS to fall around 24¢ to 27¢ for the quarter. Revenues are expected to remain in previously announced range of $19 mil. to $20.5 mil.; the company has narrowed its full-year sales guidance to $72 mil. to $75 mil. from an earlier range of $70 mil. to $75 mil. CIMA expects additional fourth quarter merger-related expenses "that the company is unable to quantify at the present time," and thus, is withdrawing full year 2003 earnings guidance...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS096032

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel